Novartis’ New Heart Failure Drug Reduces Cardiovascular Deaths by 20%

WASHINGTON - Sept. 11, 2014 - PRLog -- Novartis’ investigational medicine, LCZ696 was revealed to be superior to ACE-inhibitor enalapril on key endpoints in the largest heart failure study ever done. LCZ696 is administered in the form of a tablet and specifically works by enhancing the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful system (the RAAS). The PARADIGM-HF study conducted indicated patients with heart failure having reduced ejection fraction (HF-REF) were more likely to be alive and less likely to undergo hospitalization for heart failure in comparison to the ACE-inhibitor enalapril.

According to Novartis, fundamental clinical data revealed that LCZ696:

***reduced the risk of death from cardiovascular causes by 20% (p=0.00004)

***reduced heart failure hospitalizations by 21% (p=0.00004)

***reduced the risk of all-cause mortality by 16% (p=0.0005)

"By demonstrating a very significant reduction in cardiovascular deaths while improving Quality of Life, Novartis' new heart failure medicine, LCZ696, represents one of the most important cardiology advances of the last decade," said David Epstein, Division Head, Novartis Pharmaceuticals. "We want to thank leading cardiologists from around the world for their collaboration with us and their determination in advancing this important new life saving therapy for heart failure patients."

Heart failure affects approximately 5 million individuals in the Unites States and is one of leading causes of hospitalization. Based on the remarkable clinical results, industry analysts have helmed this treatment as the biggest breakthrough to treat heart failure in more than a decade.

Novartis is expected to reap huge sales from this drug once launched with an estimated generation of $10 billion dollars over the course of 10 years. Novartis expects an approval by the third quarter 2015 by the FDA as they plan to file by the end of 2014.

With such industry leaders paving the way with new beneficial therapeutic breakthroughs, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to sell their product both proficiently and efficiently.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.